123 related articles for article (PubMed ID: 32556179)
1. p110δ PI3K as a therapeutic target of solid tumours.
Xenou L; Papakonstanti EA
Clin Sci (Lond); 2020 Jun; 134(12):1377-1397. PubMed ID: 32556179
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
3. p110δ PI3 kinase pathway: emerging roles in cancer.
Tzenaki N; Papakonstanti EA
Front Oncol; 2013; 3():40. PubMed ID: 23459844
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages.
Goulielmaki E; Bermudez-Brito M; Andreou M; Tzenaki N; Tzardi M; de Bree E; Tsentelierou E; Makrigiannakis A; Papakonstanti EA
Cell Death Dis; 2018 Jun; 9(6):678. PubMed ID: 29880805
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
[TBL] [Abstract][Full Text] [Related]
6. Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter.
Whitehead MA; Bombardieri M; Pitzalis C; Vanhaesebroeck B
Biochem J; 2012 May; 443(3):857-67. PubMed ID: 22375552
[TBL] [Abstract][Full Text] [Related]
7. Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.
Vantler M; Jesus J; Leppänen O; Scherner M; Berghausen EM; Mustafov L; Chen X; Kramer T; Zierden M; Gerhardt M; Ten Freyhaus H; Blaschke F; Sterner-Kock A; Baldus S; Zhao JJ; Rosenkranz S
Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1434-44. PubMed ID: 25908763
[TBL] [Abstract][Full Text] [Related]
8. p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors.
Fransson S; Uv A; Eriksson H; Andersson MK; Wettergren Y; Bergo M; Ejeskär K
Oncogene; 2012 Jul; 31(27):3277-86. PubMed ID: 22020336
[TBL] [Abstract][Full Text] [Related]
9. High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.
Tzenaki N; Andreou M; Stratigi K; Vergetaki A; Makrigiannakis A; Vanhaesebroeck B; Papakonstanti EA
FASEB J; 2012 Jun; 26(6):2498-508. PubMed ID: 22391131
[TBL] [Abstract][Full Text] [Related]
10. Molecules in medicine mini-review: isoforms of PI3K in biology and disease.
Vanhaesebroeck B; Whitehead MA; Piñeiro R
J Mol Med (Berl); 2016 Jan; 94(1):5-11. PubMed ID: 26658520
[TBL] [Abstract][Full Text] [Related]
11. The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion.
Luk SK; Piekorz RP; Nürnberg B; Tony To SS
Eur J Cancer; 2012 Jan; 48(1):149-57. PubMed ID: 22079609
[TBL] [Abstract][Full Text] [Related]
12. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Sawyer C; Sturge J; Bennett DC; O'Hare MJ; Allen WE; Bain J; Jones GE; Vanhaesebroeck B
Cancer Res; 2003 Apr; 63(7):1667-75. PubMed ID: 12670921
[TBL] [Abstract][Full Text] [Related]
13. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of PI3K inhibitors for solid tumour treatment and beyond.
Belli C; Repetto M; Anand S; Porta C; Subbiah V; Curigliano G
Br J Cancer; 2023 Jun; 128(12):2150-2162. PubMed ID: 36914722
[TBL] [Abstract][Full Text] [Related]
15. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
16. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
17. The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.
Pridham KJ; Varghese RT; Sheng Z
Front Oncol; 2017; 7():312. PubMed ID: 29326882
[TBL] [Abstract][Full Text] [Related]
18. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling.
Chaussade C; Rewcastle GW; Kendall JD; Denny WA; Cho K; Grønning LM; Chong ML; Anagnostou SH; Jackson SP; Daniele N; Shepherd PR
Biochem J; 2007 Jun; 404(3):449-58. PubMed ID: 17362206
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of the PI3K catalytic subunit p110δ underlies elevated S6 phosphorylation and protein synthesis in an individual with autism from a multiplex family.
Poopal AC; Schroeder LM; Horn PS; Bassell GJ; Gross C
Mol Autism; 2016; 7():3. PubMed ID: 26770665
[TBL] [Abstract][Full Text] [Related]
20. Ligand-selective signal transduction by two endogenous GnRH isoforms involves biased activation of the class I PI3K catalytic subunits p110β, p110γ, and p110δ in pituitary gonadotropes and somatotropes.
Pemberton JG; Stafford JL; Chang JP
Endocrinology; 2015 Jan; 156(1):218-30. PubMed ID: 25343277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
